• ArrayPatch

  Participated · Seed · Feb 2026

  ArrayPatch is a biotech spin-out from University College Cork that engineers dissolvable microneedle patches composed entirely of the drug being delivered. Its proprietary DerMap platform enables pain-free, targeted delivery through the skin, addressing conditions that are difficult to treat with conventional topical or oral formulations. The company’s lead asset, ITZ-DerMap, administers itraconazole directly to the nail bed to treat onychomycosis, a large and under-served market. Funds from the current raise will be used to move ITZ-DerMap into clinical development and establish proof-of-concept data. Looking ahead, ArrayPatch is adapting the same platform for additional indications such as skin cancer, diabetes, weight loss and migraine. The startup has augmented its capital base with non-dilutive grants and has won several accolades, including the 2025 InterTradeIreland Seedcorn Investor Readiness Competition, the 2023 IDEATE Ireland competition and Innovation of the Year at the 2022 Irish Pharma Awards.

• eID Easy

  Participated · Seed · Oct 2025

  eID Easy builds a cloud-based API platform that lets organizations issue verifiable electronic identifications, signatures, and seals, replacing paper-heavy workflows with secure digital flows. Drawing on Estonia’s pioneering e-government experience, the company focuses on high reliability, security, and legal compliance for cross-border signatures. Its technology is already embedded in eight of the world’s ten leading e-signature platforms and recently became the first provider in the EU to support Ukraine’s Diia.Signature. After relocating its headquarters from Estonia to Ireland, eID Easy plans to expand its team across Europe and step up product development and sales. Including the latest financing, the startup has secured a total of €2.4 million to date, underscoring early market traction and investor confidence.

• SymPhysis Medical

  Participated · Equity · Dec 2023

  SymPhysis Medical is building Releaze, a port-style drainage system that combines a safety-valve catheter with a compact external hub, allowing patients and carers to relieve malignant pleural effusion at home instead of enduring repeated hospital procedures. The condition, which causes painful fluid build-up in the chest, affects more than 150,000 people annually in the United States, and Releaze aims to improve comfort and reduce hospital visits for these patients. Headquartered in Galway, the company has worked closely with Irish clinicians, nurses, patients and carers to design and refine the device. With the new U.S. grant, SymPhysis Medical will open its first American base in Rhode Island, advance testing and move toward its initial FDA regulatory clearance. The firm also plans to build partnerships across New England’s life-sciences cluster while continuing to expand engineering and operations in Ireland. To date, the company has raised over €4 million from Irish and European investors and health-innovation programmes, adding to the latest U.S. public-sector funding. These combined resources provide the runway to progress Releaze toward early international commercialisation.

• FeelTect

  Participated · Equity · Dec 2023

  FeelTect’s core product, Tight Alright, integrates disposable pressure sensors with a reusable transmitter and cloud platform to give clinicians real-time data on sub-bandage pressure during compression therapy. By keeping pressure within therapeutic ranges, the technology aims to shorten healing times and cut overall treatment costs for chronic wounds. After multi-year clinical validation, the company is moving from pilot studies to its first commercial deployment at Thun Hospital in Switzerland. The recent funding will finance a broader commercial roll-out, regulatory expansion into additional markets, and team growth at its Spiddal, Galway base. FeelTect previously secured a similar capital injection in 2023 to fund product finalisation and early market preparation. Investors across the two rounds include Irrus Investments, the Western Development Commission, Halo Business Angel Network, and other individual angels. The company has not yet disclosed revenue or user numbers but positions itself to become a global leader in compression-therapy monitoring.

No current team members are available.